Mori Shusuke, Kishimoto Hirofumi, Tauchi Katsunori, Higuchi Kayoko
Department of Surgery, Aizawa Hospital, 2-5-1 Honjou, Matsumoto, Nagano 390-8510, Japan.
Gastric Cancer. 2006;9(2):136-9. doi: 10.1007/s10120-005-0358-z.
Single-agent or combined chemotherapy with the novel oral fluoropyrimidine anticancer drug, S-1 (TS-1), has been reported to be useful for the treatment of advanced gastric cancer. Here, we report a patient with advanced gastric cancer achieving a complete response (CR) after 2 weeks of administration of S-1 as neoadjuvant chemotherapy. A 78-year-old woman with epigastric pain was diagnosed as having advanced gastric cancer. S-1 was administered orally, at a dose of 50 mg twice a day every day for 2 weeks, followed by a 2-week drug-free period. No obvious adverse reactions occurred. Subsequently, the patient underwent distal partial gastrectomy with D2 lymph node dissection. Pathological examination indicated no remnant signet-ring cells in the excised specimen, no lymph node metastasis, and unnatural fibrosis in one of the No. 3 lymph nodes. The neoadjuvant chemotherapy induced a CR according to the Japanese classification of gastric carcinoma.
据报道，新型口服氟嘧啶类抗癌药物S-1（TS-1）单药或联合化疗对晚期胃癌的治疗有效。在此，我们报告1例晚期胃癌患者，在接受S-1新辅助化疗2周后达到完全缓解（CR）。1名78岁上腹部疼痛的女性被诊断为晚期胃癌。口服S-1，剂量为50mg，每天2次，共2周，随后为2周的无药期。未发生明显不良反应。随后，患者接受了D2淋巴结清扫的远端部分胃切除术。病理检查显示，切除标本中无残留印戒细胞，无淋巴结转移，第3组淋巴结之一有非自然纤维化。根据日本胃癌分类，新辅助化疗诱导出CR。
